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Abstract
Less than 100 nm in size and spherical in form - exosomes
– vesicles expelled and taken up by cells, have ignited a
new-found fascination. One which is derived from the
sheer variety of exosomal content, ranging from micro‐
RNAs to transcription factors, capable of affecting a
multitude of processes and pathways simultaneously
within a target cell. Initially dismissed in 1983 as a waste
disposal mechanism, today they form an entire field of
research, being documented thus far in invertebrates,
mammals, pathogens and potentially some plants. Many
studies have suggested these spherical enigmas may
possess a function, being implicated in processes ranging
from animal behaviour to viral infection. This review will
evaluate the evidence for the role of exosomes in physiol‐
ogy and pathophysiology, as well as their potential for
application in the diagnosis and treatment of disease.
Keywords Exosomes, Physiology, Disease, Diagnostics,
Diagnosis, Therapeutics, Treatment
1. Introduction
Within our bodies, there exist minute space shuttles,
making contact with unknown lands and, in the process,
reshaping them. This is the world of exosomes - bubble -
like spheres that bud off from cells containing a concoction
of lipids, proteins and genetic material as their cargo. Less
than 100 nm in size, these vesicles possess the potential
upon landing to not only alter a target cell's metabolism but
ultimately function [1]. Initially reported in red blood cells
[2] and once dismissed as mere ejection pods removing
cellular waste, today they stand at the forefront of research
into intercellular, interorganismal and interspecies com‐
munication [1, 3, 4]. Documented thus far in mammals
[5-7], invertebrates [8-9], pathogens [10] and potentially
some plants [11], exosomes offer a way for the world
around us and ourselves to interact, both in health and
disease [12]. Indeed, the processes in which they are
implicated reflect this, ranging from animal behaviour [13]
to viral infection [14]. Their presence in a variety of bodily
fluids, from cerebrospinal fluid to urine, make them readily
accessible, be it for study or as diagnostic tools [15]. As
decoding of exosomal signalling advances, what does this
hold for our understanding of disease and our attempts to
alleviate it?
Exosomes form one part of a larger universe – that of
extracellular microvesicles (MVs), which are broadly
divided into exosomes, ectosomes and apoptotic vesicles.
Ectosomes are vesicles that directly budd off from the
plasma membrane without involving the endocytic
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pathway, whilst apoptotic vesicles are remnants of cells
that have undergone programmed cell death [12]. This
review will primarily focus on exosomes, as many studies
have indicated that they may possess a biological function
[10, 13, 14, 16-21], as well as being useful in diagnosis [15]
and treating disease [22].
Importantly, many exosome studies rely on vesicle size and
biomarkers to fractionate and identify exosomes – a crude
technique at best, which may mean that investigators are
often studying a much more complex mixture of extracel‐
lular vesicles. However, the findings from these studies, the
questions they raise and their implications, if true, make
them highly significant.
One must first look at exosomal biogenesis [12, 23-28] (Fig.
1) in order to recognize the normal state of affairs and how
this provides avenues for exploitation, both therapeutically
and by pathogens. Within a cell, as part of the endocytic
pathway, a region of the plasma membrane invaginates,
forming a vesicle that enters the cytoplasmic space,
carrying with it cell surface receptors and extracellular
fluid – an early endosome. As endosomes mature, they
become more acidified and act as a sorting site, recycling
certain proteins whilst targeting others for degradation. In
these late endosomes, known as multivesicular bodies
(MVBs), invaginations of the endosomal membrane also
occur, forming numerous intraluminal vesicles (ILVs) that
contain cytoplasmic content, such as short interfering RNA
(siRNA). MVBs can then fuse with a lysosome, where
proteins are degraded, or with the cell’s plasma membrane,
releasing the ILVs – now known as exosomes – into the
extracellular space. The power of exosomes as signalling
agents arise from the sheer variety of the contents they
carry – capable of affecting a multitude of processes and
pathways simultaneously within a target cell: from
microRNAs, which prevent translation of mRNAs [29], to
proteins, which can act as transcription factors [30] or even
emit oncogenic phenotypes [31].
2. Exosomes in Physiology and Pathophysiology
2.1 Cancer
Exosomes appear to act as vehicles of transmission when
hijacked. Perhaps the most well-known case is cancer, in
which exosomes are thought to contribute to the creation
of a microenviromental niche that promotes cancer cell
survival (Fig.2), as well as reprogramming distant tissue for
invasion [33]. Take, for example, exosomes from Epstein
Barr Virus (EBV) transformed lymphoblastoid B cells,
containing miRNA: when exposed to dendritic cells (DCs),
they lead to dose-dependent suppression of the immunor‐
egulatory gene CXCL11/ITAC - known to be a target of EBV
in promoting lymphomas. The peripheral blood of patients
with EBV reveals EBV miRNA to be present in non–B cell
populations, unlike EBV-DNA, which further suggests that
miRNA transfer occurs in vivo [34].
Moreover, we are beginning to unveil how exosomes may
mediate metastasis. Injection of the fluorescently labelled
pancreatic cancer cell line - PAN02- derived exosomes, has
confirmed their ability to increase the metastatic load in the
liver of mice [35]. Other pancreatic cell-line-derived
exosomes, including human BxPC-3 exosomes, also
display a preference for the liver. Subsequent experiments
have demonstrated that exosomal uptake by Kupffer cells
leads to TGF-β synthesis and release, activating hepatos‐
tellate cells that go onto express fibronectin. This, then,
attracts bone marrow-derived macrophages and granulo‐
cytes, which are now determined to be a prerequisite for
metastasis, opening an avenue for future work.
Figure 1. This depicts early endosome invagination from the plasma membrane of a cell. As the endosome matures to become a late endosome, endosomal
membranes invaginate forming ILVs, giving rise to an MVB. Proteins from the Golgi complex can join the endosome prior to ILV formation as well as after.
MVBs can then fuse with a lysosome, which enables proteasomal degradation, or with the plasma membrane releasing ILVs – now termed exosomes – into
extracellular space. Adapted from[32],this figure was produced using Servier Medical Art, available from www.servier.com/Powerpoint-image-bank.
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However, in both cases it is important to note that arbitrary
exosomal concentrations were used, sometimes in vitro and
further research is needed to establish what truly occurs in
vivo.
Nonetheless, when considered with studies illustrating
exosomal explusion of cancer drugs [36-39], exosome-
induced agiogenesis [40-43] and promotion of fibroblast
differentiation and fibroblast-like cell formation, which
sheaths the caner in a fibrous layer acting as a barrier (e.g.,
to drugs) [44-46] – exosomes add to the Darwinian para‐
digm of cancer cells as an evolving agent, with those
capable of manipulating the cell machinery gaining a clear
advantage in self- propagation.
2.2 HIV
HIV dissemination also involves rerouting of cellular
behaviour. In which case, could exosomes play a similar
role here? Conventionally, infected immature DCs are
thought to travel to the lymph node, where they mature to
interact with CD4+T cells, transferring the infection and
resulting in CD4+ T-cell depletion with accompanying
catastrophic immunodeficiency [48]. Recent work, which
pulsed HIV-1 with DCs, showed not only increased
exosomal release from infected DCs, but also that these
exosomes promoted apoptosis when exposed to CD4+ T-
cells [14]. How infection can be maintained, when given the
short half-lives of CD4+ T-cells (less than two days),
remains a puzzle. HIV is known to be able to enter DCs via
endocytosis (transinfection), rather than direct fusion with
the plasma membrane. The Trojan exosome hypothesis,
therefore, proposes that HIV enters DCs in this alternative
fashion, becoming part of the endosome and being later
released into the extracellular space with exosomes. This
means that CD4+ T-cells, which are rapidly transcribing
and translating HIV, and are soon likely to die, can transfer
HIV to DCs, which frequently interact with naïve CD4+ T-
cells, thereby maintaining the infection. Confocal micro‐
scopy and various other imaging techniques have shown,
via visualization, that the above is certainly possible in
vitro, while in vivo effects remain to be established.
2.3 Physiology
Just as exosomes can become agents of dissemination, they
may otherwise act as agents of control within the body
when unaffected. Presentation of MHC-peptide complexes
or antigens by DC-derived exosomes is capable of eliciting
antigen-specific immune responses from other DCs [1]. The
effect of exosomes appears to be dependent on the cell type
of origin and the physiological state of the said cell type.
Whilst exosomes from DCs can be immunostimulatory,
cancer cell exosomes contain both cancer cell antigens, that
could potentially be used to activate the immune system,
and immunosuppressive molecules in vivo. Establishing
which of the aforementioned effects is more dominant
remains to be determined. When DCs are exposed to
immunosuppressive chemicals or altered in order to
transcribe immunosuppressive cytokines, this change in
their physiology appears to promote tolerance by the
exosomes secreted instead.
Whilst roles in immune regulation emerge, exosomes are
also known to be expelled by neurons [49], microglia [20]
and possibly adipose tissue [50] – could any regulatory role
extend beyond immunity to territories, such as neuroen‐
docrine physiology? In unravelling exosomal physiology
and pathophysiology, we currently lack an established
model to study exosomes in vivo. This is further complicat‐
Figure 2. Some emerging roles of exosomes in cancer. Top left: promotion of nearby cells to act like fibroblasts secreting and sheathing the cancer in a fibrous
layer that acts as a barrier, e.g., to drugs. Top right: promotion of new blood vessel growth and metastasis. Bottom left: aiding epithelial-mesenchymal transition
(EMT) – with cells becoming capable of expressing a variety of proteins, as well as leaving the original site. Bottom right: enabling survival from immune
response. Exosomal miRNA may be an important contributor to all of the above. Adapted from [33].This figure was produced using Servier Medical Art,
available from www.servier.com/Powerpoint-image-bank.
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ed by our current techniques for selectively enriching and
studying exosomes in vitro being too reliant on size and
biomarkers - features no longer accepted as effective in
completely removing other microvesicles from the sample
[12]. Are any of the effects seen in vitro truly due to exo‐
somes, or even reflective of physiological concentrations
and their effect? One way of overcoming this hurdle would
be to knockout genes known to be involved in exosomal
regulation in a simple invertebrate model, such as C.
elegans. These knockouts can be both systemic and tissue-
specific in order to determine any functional consequence.
One group of candidates for this would be the ESCRT
proteins, which are known to regulate MVB and ILV
formation [12, 51]. However, as they are also involved in
degradation of ubiquitylated proteins, when a MVB fuses
with a lysosome, protein turnover could be affected.
Experimental models, therefore, would need to take this
into account and distinguish any effects due to changes in
exosomal biogenesis from the latter.
Despite the concerns raised above, perhaps the strongest
evidence for exosomal functionality in vivo would be work
done on Drosophila melanogaster [13]. Secondary cells of
male accessory glands, equivalent to the prostate, were
shown to release GFP-tagged exosomes in to the seminal
fluid, which not only “fuse with sperm in vivo” but also
interact with the epithelium of the female genital tract,
specifically reducing remating in females and, thus,
providing an evolutionary advantage to the male Drosophi‐
la. When exosomal production is blocked in secondary
cells, via removing proteins required for exosomal biogen‐
esis, either by RNA interference or dominant negative
RAB11 expression, 50-60% of males were unable to prevent
remating in females, compared to 18% in the control group.
It is remarkable to consider that something as minute as an
exosome may bring about a change in something as
biologically complex as behaviour. Furthermore, the
observation of exosomal fusion with sperm is concordant
with in vitro studies on human sperm, where prostate-
derived exosomes (prostasomes) contribute to sperm
motility [16].
3. Exosomes as Diagnostic Tools
From a diagnostic point of view, it does not matter whether
exosomes have a function or not – only that a significant
difference exists, either in composition or presence in both
sickness and health, with these differences then being
specific and attributable to different ailments. Indeed, this
appears to be the case for many pathological conditions,
with both exosomal content and presence varying [12]
(Table 1).
One interesting study concerns exosomes fractioned from
the blood of pregnant women with no history of any
previous pregnancies at 28-30 weeks of gestation [60].
Significant differences existed between those going on to
deliver at term and those delivering prematurely: specifi‐
cally, lower levels of FAS L, HLA-DR and reduced inhibi‐
tion of JAK3 and CD3 zeta in premature births. Could an
exosomal screening programme be the future? Given the
small sample size, more work is needed before any clinical
translation can occur.
In cancer, however, the use of exosomes in diagnostics
appears more imminent. Exosome Diagnostics have
developed a “urine-based liquid biopsy” which looked at
three specific exosomal RNAs prior to prostate biopsy in
195 men. It was found that high grade cancer could be
predicted based on a score derived from RNA levels alone,
with a sensitivity of 95.2% and a negative predictive value
of 97.5% [65]. Exosome Diagnostics points to the use of a
first catch urine sample and a single score that can prevent
unnecessary biopsies in low grade tumours as key advan‐
tages. Additional research looking at economics and
outcomes is underway, as well as expansion into “blood
plasma-based liquid biopsy” [66]. Further excitement in
this field arrived with a recent attempt to detect cancer
exosome specific biomarkers. Primary work on cancer cells
and other non-cancer lineages using mass spectrometry
suggested 48 proteins [57]. Of these, glycoprotein glypican
– 1 (GPC1), which, although found circulating at low levels
in healthy patients sera, was higher in patients with breast
cancer (n = 32, 75%) and pancreatic ductal adenocarcinoma
Table 1. Examples of body fluid exosomal markers (specifically, some of the proteins and RNAs) associated with pathology. Modified from [15, 52]
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(PDAC, n = 190, 100%). Analysis of a small group of patients
revealed that GPC1 levels distinguished precursor lesions
(n=5) from benign pancreatic disease (pancreatitis & cystic
adenomas, n = 18) - something that could not be done by
the current tumour marker for pancreatic cancer, CA-19-9.
ROC curve comparison of CA-19-9 and GPC-1 showed the
latter to be superior at all stages of PDAC with 100%
sensitivity and specificity, as well as positive and negative
predictive value. Whilst the prospect of an early exosomal
marker for pancreatic cancer is joyous, the nature of the
small cohorts in this work means that further confirmation
is required.
Exosomes offer three key advantages as a diagnostic tool:
they are less invasive compared to a biopsy, they can be
used where a biopsy is not possible (e.g., brain tumour) and
may become cost-effective and time-efficient [67, 68].
Although the most common techniques of exosomal
fractioning, which are ultracentrifugation and density
gradient separation can require over five hours [69], work
is already underway to overcome this. One promising
avenue is microfluidic-based exosomal detection, which is
essentially a “lab on a chip” [68]. The prototype consists of
various chambers, inlets and a microchannel within a
polydimethylsiloxane chip, enabling integration of several
processes. This includes exosomal isolation and enrich‐
ment, as well as the detection of biomarkers from minute
volumes of plasma (30 μl). Initially, a plasma sample is
mixed with magnetic beads coated in antibodies to desired
surface markers, and injected via an inlet. A magnetic field
is then applied, trapping the exosomes bound to the beads,
with subsequent washing in a PBS solution. Following this
separation and enrichment, incubation with a lysis buffer,
which is inserted via another inlet, releases exosomal
content. Next, the lysate moves through a winding channel,
with magnetic beads coated in antibodies flowing from the
two side channels, targeting inter-exosomal content of
interest. Bead-inter-exosomal content is then trapped in a
chamber via a magnetic field, where chemifluorescence
detection can be carried out, meaning levels of specific
inter-exosomal content can be measured. This technique
not only takes one and a half hours, but was also successful
in identifying the insulin-like growth factor 1R (IGF-1R) –
a potential biomarker for non-small cell lung cancer
(NSCLC), in plasma of patients with NSCLC. It is also
possible to embed exosomes extracted in this manner and
view them under transmission electron microscopy,
thereby enabling higher levels of characterization. With
greater mapping of disease-specific exosomal markers, the
use of microfluidic technology, such as this routinely, may
become a reality.
4. Exosomes as Therapeutic Tools
One of the features that makes exosomes useful in diag‐
nostics also means they can be useful therapeutically.
Essentially, exosomal surface markers can be used to target
specific cell types. Be it for drug delivery or gene therapy,
exosomes engineered and secreted by a chosen cell type can
be packaged with desired components [22] and adminis‐
tered by a simple injection [70]. Another appealing feature
is the use of patients’ own cells to generate exosomes in
order to enable biocompatibility [22]. Although therapy is
the most ambitious and fledgling aspect in exosomal
research, its untapped potential is worth considering.
Take the brain for instance - one of the most difficult places
to deliver any kind of therapy within the human body. This
is due to the blood-brain barrier, restricting what may and
may not enter, in an attempt to protect the neural cavity
[71]. However, exosomes are known to be released by
neurons within the brain parenchyma [34], as well as
transport pathological agents, such as alpha–synuclein
between neurons in Parkinson’s [17]. Recently, rat choroid
plexus-derived exosomes were shown to distribute folate -
vital for DNA synthesis via cerebrospinal fluid [19]. Work
on C57BL/6 mice removed their bone marrow, selecting
immature DCs known to produce copious amounts of
exosomes that are non-T-cell stimulatory [70]. These cells
were then transfected with plasmids expressing targeting
peptides; in the case of the brain, these were rabies virus
glycoprotein (RVG). This led to formation of exosomes with
desired surface markers. Next, electroporation was adapt‐
ed and applied at the nanoscale in order to enable exosomal
uptake of exogenous SiRNA. RVG9R exosomes were also
created with the addition of nine D-arginines to the RVG,
which interacted electrostatically with loaded SiRNA.
SiRNA to BACE1 (a key gene in Alzheimer’s) containing
RVG exosomes were injected into C57BL/6 mice. Controls
included untreated mice and mice injected with RVG9R–
BACE1. Three days later, cortical tissue analysis revealed
significant protein knockdown (45%, P < 0.05, versus 62%,
P < 0.01) when RVG9R-BACE1 and RVG-BACE1 were used,
respectively. β-amyloid 1-42 levels, an important constitu‐
ent of amyloid plaques, fell by 55% (P <0.01) in mice treated
with RVG exosomes, whilst serum markers of an inflam‐
matory response (IFN - α, TNF – α, IL - 6, IP-10) were not
increased. The ability to cross the blood-brain barrier is
perhaps a pharmacological holy grail; like the holy grail,
however, whether one should obtain it remains a question.
Can we treat in the vicinity of such a delicate and vital
organ? Although the same question could have been asked
at the advent of bypass surgery, which is now almost
routine.
Moreover, in situations such as immune-mediated loss of
beta cells of the pancreas (Type I diabetes) [72] or scarring
of cardiac tissue post-myocardial infarction (MI) [73], a
promising regenerative strategy has been stem cell implan‐
tation [74]. However, in some cases at least, it may be the
exosomes released by stem cells that deserve credit. For
example, a recent study showed that cardiosphere-derived
stem cells (CDCs), when infused via coronary circulation
in post-MI patients, led to decreased scar formation and
increased viable mass at six months [75]. More interesting‐
ly, when CDCs were inhibited from releasing exosomes in
a murine model of MI, they were unable to reproduce the
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above effects. Furthermore, CDC-derived exosomes alone
could produce the regenerative effects displayed by CDCs
[18]. This offers a potential cell-free approach to regenera‐
tive medicine, if applicable to other stem cells.
Another avenue is the use of exosomes as vaccines [76-78].
Here, the ability of mature DCs to create immunostimula‐
tory exosomes could be exploited, via presenting DCs with
pathologic antigens before injection of generated exo‐
somes. Largely thus far explored in cancer, its application
could be broader if successful. Work using DCs, which are
pulsed with tumour antigens as cancer vaccines, appears
to be more potent at generating anti-tumour immunity than
other techniques (e.g., viral vaccines). It remains to be seen
whether exosomes can match, if not better, this. Equally, in
the treatment of autoimmune disease, the creation of
immunosuppressive exosomes by altered DCs may be
useful [1].
5. Conclusion
What were once dismissed as waste disposal agents have
now become an entire field of study [1]. With an ever-
growing list of potential applications and investment
opportunities, our knowledge regarding extracellular
communication is likely to expand in the next decade.
Success will rely crucially on the development of an in
vivo model for determining exosomal function. Whilst the
current work on therapeutics and diagnostics is promising,
much remains to be seen as to how it will play out clinically.
Will it be safe? Will we be able to transform concept into
reality? Despite the gathering interest, numerous un‐
knowns remain. However, this should not be a hindrance
to progress – if anything these questions ought to dictate
further research and exploration into a tantalizing field.
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